Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim Drevs

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Idrugs : the Investigational Drugs Journal|August 15, 2003
PTK/ZK (Novartis)Joachim Drevs
Anticancer Research|June 25, 2003
Soluble markers for the detection of hypoxia under antiangiogenic treatmentJoachim Drevs
Current Pharmaceutical Design|April 28, 2005
Receptor tyrosine kinases and anticancer therapyMichael Medinger, Joachim Drevs
Expert Review of Anticancer Therapy|May 19, 2009
Mode of action and clinical impact of VEGF signaling inhibitorsJens Soltau, Joachim Drevs
Idrugs : the Investigational Drugs Journal|April 2, 2004
ZD-6126 AstraZenecaJens Soltau, Joachim Drevs
World Journal of Hepatology|March 23, 2011
Liver cancer: Targeted future optionsAndreas Pircher, Michael Medinger, Joachim Drevs
Oncology Letters|September 3, 2016
Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imagingRegina Willecke-Hochmuth, Katharina Pachmann, Joachim Drevs
Anticancer Research|February 26, 2004
Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinomaJoachim Drevs, Roland Löser, Benno Rattel, et al.
Oncology Reports|September 3, 2009
A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life dataJürgen Scheele, Faiz Niazi, Joachim Drevs, et al.
Current Drug Targets|February 1, 2003
Receptor tyrosine kinases: the main targets for new anticancer therapyJoachim Drevs, Michael Medinger, Carmen Schmidt-Gersbach, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Idrugs : the Investigational Drugs Journal|August 15, 2003
PTK/ZK (Novartis)Joachim Drevs
Anticancer Research|June 25, 2003
Soluble markers for the detection of hypoxia under antiangiogenic treatmentJoachim Drevs
Current Pharmaceutical Design|April 28, 2005
Receptor tyrosine kinases and anticancer therapyMichael Medinger, Joachim Drevs
Expert Review of Anticancer Therapy|May 19, 2009
Mode of action and clinical impact of VEGF signaling inhibitorsJens Soltau, Joachim Drevs
Idrugs : the Investigational Drugs Journal|April 2, 2004
ZD-6126 AstraZenecaJens Soltau, Joachim Drevs
World Journal of Hepatology|March 23, 2011
Liver cancer: Targeted future optionsAndreas Pircher, Michael Medinger, Joachim Drevs
Oncology Letters|September 3, 2016
Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imagingRegina Willecke-Hochmuth, Katharina Pachmann, Joachim Drevs
Anticancer Research|February 26, 2004
Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinomaJoachim Drevs, Roland Löser, Benno Rattel, et al.
Oncology Reports|September 3, 2009
A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life dataJürgen Scheele, Faiz Niazi, Joachim Drevs, et al.
Current Drug Targets|February 1, 2003
Receptor tyrosine kinases: the main targets for new anticancer therapyJoachim Drevs, Michael Medinger, Carmen Schmidt-Gersbach, et al.
Pageof 4